Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, single blind, randomized parallel group study to assess the short and long term efficacy of certolizumab pegol plus methotrexate compared with adalimumab plus methotrexate in subjects with moderate to severe rheumatoid arthritis responding inadequately to methotrexate

Next Previous
X
Search
Trial Profile

A multicenter, single blind, randomized parallel group study to assess the short and long term efficacy of certolizumab pegol plus methotrexate compared with adalimumab plus methotrexate in subjects with moderate to severe rheumatoid arthritis responding inadequately to methotrexate

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Certolizumab pegol (Primary) ; Adalimumab; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms EXXELERATE
  • Sponsors UCB Pharma SA

    • Most Recent Events

    • 15 Nov 2023 Results of post-hoc analysis assessing efficacy outcomes of certolizumab pegol versus adalimumab in patients with RA and high RF titers, presented at the ACR Convergence 2023.
    • 11 Nov 2023 Post hoc analysis results presented in a UCB Media Release.
    • 11 Nov 2023 According to UCB media release, data from post hoc analysis of this study are being presented at the American College of Rheumatology (ACR) Convergence 2023 in San Diego,

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top